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The present study examined effects of testosterone on hypoactive sex-
ual desire in pre- and postmenopausal women (treated) compared
with an age-matched reference group (reference). Treated partici-
pants received 100 mg of testosterone cypionate in oil injected in-
tramuscularly (i.m.) monthly for 3 months. We measured salivary
testosterone and scores on the Sexual Desire Inventory pretreatment
and posttreatment. Treated and reference participants’ baseline
testosterone was equivalent, however, treated participants exhibited
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higher testosterone levels than did reference participants posttreat-
ment. As expected, treated participants exhibited lower baseline sex-
ual desire than did reference participants and showed a significant
increase in sexual desire posttreatment. This research suggests that
testosterone may effectively alleviate hypoactive sexual desire, even
in women with normal testosterone levels.
Hypoactive sexual desire (HSD) is the most common sexual complaint among
women (Davis, 1998; Michael, Gagnon, Laumann, & Kolata, 1994; Talakoub
et al., 2002). Recent estimates of prevalence range from 27% to 33% in
nonclinical samples of women aged 18–59 years in the United States (Michael
et al., 1994; Laumann, Paik, & Rosen, 1999) and from 21% to 53% among
Canadian women of reproductive age (Fisher, Boroditsky, & Bridges, 1999).
The etiology of HSD is multifaceted and may involve a range of factors from
the biological to psychosocial. Basson (2001) found that all women seek-
ing clinical attention for HSD reported a dynamic interplay of more than one
causal factor. For example, psychosocial correlates of HSD include inability to
relax (Frank, Anderson, & Rubenstein, 1978), poor marital adjustment (Stuart,
Hammond, & Pett, 1987), and insufficient emotional intimacy (Basson, 2001).
Psychological approaches to the treatment of HSD address these or other is-
sues through individual or couple counseling and therapy.
Endocrine foundations of HSD have also been investigated. Research
suggests that androgens are the primary hormones supporting female sexual
desire (reviewed in Bachmann, 2002). Although there is strong evidence
of a link between low levels of estrogens and sexual dysfunctions (e.g.,
dyspareunia; Decker et al., 2003; reviewed in Basson, 2002; Traish, Kim,
Munarriz, Moreland, & Goldstein, 2002), estrogenic deficiencies appear to
be causally linked to “mechanical” difficulties, including decreased vaginal
lubrication and genital blood flow, and not to low sexual desire, per se
(Sarrel, 2000).
Low androgen levels and HSD are two signs of a condition tentatively
referred to as hypoandrogenism (Bachmann, 2002) or female androgen insuf-
ficiency syndrome (Bachmann et al., 2003). However, there is little consensus
regarding the threshold levels of androgen that define this syndrome or that
are required for normal sexual desire (Basson, 2001).
Despite these unresolved issues, HSD is associated with low androgens,
primarily testosterone (T; e.g., Sarrel, 2000; Sherwin, 1988). For example,
Basson (2001) reported that 25% of patients seeking attention for sexual dys-
functions exhibited androgen deficiencies. Further evidence supports the low
androgen–HSD relationship. In a small clinical study of 12 premenopausal
women with HSD, eight exhibited low levels of T (Guay, 2001). Women
with HSD have significantly lower T than controls with intact sexual drives
(Riley & Riley, 2000). A similar relationship between androgens and sexual
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desire exists in postmenopausal women; Guay and Jacobson (2002) found
that nearly 75% of postmenopausal women with HSD had lower androgens
than published norms. Davis, Gilbert, Misiowiec, and Riegel (2003) found
that pre-, peri- and postmenopausal women receiving androgen supplemen-
tation with and without estrogen replacement therapy (ERT) perceived im-
provements in their sexuality, including constructs relevant to sexual desire.
Finally, Goldstat, Briganti, Tran, Wolfe, and Davis (2003) found that in healthy
premenopausal women presenting with low libido and T in the lower three
quartiles of the normal range, T therapy increased sexual self-ratings. Thus,
evidence supports an association between sexual desire and androgen levels.
Testosterone is synthesized in females from three major sources: the
adrenal glands, the ovaries, and conversion in adipose or other peripheral
tissues from prohormones (Bachmann, 2002; Burger, 2002; Luu-The, Dufort,
Pelletier, & Labrie, 2001). HSD originating from androgen deficiencies may re-
sult from ovarian or adrenal deficits. Ovarian androgen output decreases with
age as ovarian tissues begin to atrophy (Bachmann, 2002; Burger, Dudley,
Cui, Dennerstein, & Hopper, 2000; Davis, 1999), but there is no dramatic
decrease in androgen levels associated with natural menopause. In contrast,
it has long been established that women experiencing surgical menopause
have decreased levels of androgens and sexual desire (Waxenberg, Drellich,
& Sutherland, 1959).
HSD experienced by women in surgical or natural menopause is al-
leviated by androgen treatment, above the benefits gained from ERT. This
includes naturally menopausal (Greenblatt, Barfield, Garner, Calk, & Harrod,
1950; Lobo, Rosen, Yang, Block, & Van Der Hoop, 2003; Sherwin, 2002)
and surgically menopausal women (Gelfand, 1999; Shifren et al., 2000). Al-
though ERT has been shown to maintain vaginal lubrication, increase pelvic
blood flow, and decrease vaginal atrophy (Sarrel, 2000), it acts to increase
sex-hormone binding globulin (SHBG), which actually decreases bioavail-
able T. ERT without androgens may well have a negative impact on sexual
desire because of the increase in SHBG and the corresponding decrease in
bioavailable T (Basson, 1999).
Androgens and sexual desire have been examined largely in correla-
tional studies (e.g., Riley & Riley, 2000). Few studies of androgen supple-
mentation have employed reference groups, except studies of ERT in nat-
urally postmenopausal women (e.g., Sherwin, 2002). Munarriz et al. (2002)
examined effects of androgens on sexual desire in women and found that
as androgens increased from the lower third to upper half of the normal
female range, sexual function, including sexual desire, improved. However,
this study did not control for use of ERT or oral contraceptives and lacked
both a control group and statistical treatment. Guay (2001) examined an-
drogen treatment, which improved sexual desire in six of eight women pre-
senting with HSD and low androgen levels, although again there was no
control group or statistical treatment. In a well-controlled study, Tuiten et al.
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(2000) found that a single dose of T increased genital arousal in healthy pre-
menopausal women, which was significantly associated with “sexual lust.”
However these women did not have HSD, and sample size was small.
Overall, research has established that psychosocial and androgenic fac-
tors influence female sexual desire. Statistically evaluated research using ERT
and androgens in postmenopausal women has examined androgens and sex-
ual desire correlationally as well as experimentally. To our knowledge, there
is no statistical study that uses a reference group and controlling for vari-
ables that influence T to examine T administration without ERT in women
with HSD. The current study examines the effects of T treatment in women
seeking attention for HSD compared with a reference group.
METHODS
Participants
Participants were offered enrollment in the study by the clinical coinvesti-
gators while receiving care from them. Participants were explicitly reassured
that their decision to participate or not to participate in this research would
not affect their medical care in any way. Women were excluded from partici-
pation if they had any major health conditions or a known sexual dysfunction
other than HSD.
Women presenting with HSD who elected to be treated by T and who
consented to participate constituted the treatment group. Age-matched pa-
tients presenting for routine annual pelvic examinations and who consented
to participate constituted the reference group. Pre- and postmenopausal
women were recruited. Some women in both groups were using antihy-
pertensives, but no women were using hormonal contraceptives, ERT, or
psychotropic medications. The treated women were treated only with T and
did not receive adjunct counseling.
Initially, the research sample included 37 participants. With attrition, the
final sample was 33: premenopausal reference (N = 3, mean age = 40, SD =
6.24); postmenopausal reference (N = 11, mean age = 54.82, SD = 6.78);
premenopausal treated (N = 5, mean age = 36, SD = 3.16), although one
woman discontinued prior to completion; postmenopausal treated (N = 14,
mean age = 49.79, SD = 8.71). There was no significant difference in age
between treatment and reference groups. Reported reasons for attrition in-
cluded: distance from doctor’s office, dislike of injections, scheduling con-
flicts, unwelcome mood disturbances, and unwanted excess hair.
Materials
Women in the treated group received a 1-mL dose of T cypionate
(Depotestosterone, Upjohn), injected IM in oil at 100 mg/ml 1 time per month
Androgen Administration for HSD 177
for 3 months. We chose this dose because of past clinical experience sug-
gesting effectiveness without undesirable side effects.
We used the Sexual Desire Inventory (SDI; Spector, Carey, & Steinberg,
1996) to assess sexual desire. We modified the SDI by adding one question,
“During the last month, how often have you had sexual thoughts?” We scored
the SDI was in accordance with Spector et al. (1996), except that we inflated
the total SDI scores by the addition of the extra item. The SDI produces total,
solitary, and dyadic SDI scores. In Spector, Carey, & Steinberg (1998), the SDI
showed a test-retest reliability of 0.76 over a 1-month period. The SDI has
been validated in other studies (Galyer, Conaglen, Hare, & Conaglen, 1999;
King & Allgeier, 2000; Spector & Fremeth, 1996; Spector et al., 1996). In the
present study, the dyadic and total SDI subscales showed excellent reliability,
with alpha coefficients greater than 0.88; the solitary subscale showed internal
consistency, with the alpha coefficient greater than 0.65.
Procedure
All participants gave informed consent. To assess baseline HSD in treated
women, the clinical coinvestigators conducted a clinical evaluation through
interviews, examining the participants’ clinical histories, including informa-
tion about past sexual function, sexual arousal, orgasms, other sexual events,
and frequency of sexual night dreams, sex play, and sexual thoughts. Scores
ranged from slightly to extremely inhibited sexual desire.
At the first testing point, participants provided a baseline saliva sample
and completed the pretreatment SDI. We chose saliva because it yields a
direct measure of the bioavailable fraction of the hormone. Saliva and serum-
free T concentrations are highly correlated, r = 0.91 (Navarro, Juan, Bonnin,
& Villabona, 1986), r = 0.94 (Wang, Plymate, Nieschlag, & Paulsen, 1981).
At the second testing point, participants provided the second baseline saliva
sample, and treated women received the first T injection. Treated women
received a second injection approximately 1 month after the first injection. At
the third testing point, all participants provided the first posttreatment saliva
sample, and treated women received the third injection. At the fourth testing
point, all participants provided the second posttreatment saliva sample and
completed the posttreatment SDI.
Thus, we measured bioavailable T at four points via saliva samples, two
at pretreatment and two at posttreatment. We measured SDI scores twice,
one pretreatment and one posttreatment. For premenopausal treated and
reference participants, testing occurred during menses and at midcycle at
pretreatment and during their third menstrual cycle. For postmenopausal
women, testing occurred at two points separated by 2 weeks at pretreatment
and 3 months following. Most samples were collected between 8:30 a.m. and
9:45 a.m.; four were collected between 10:00 a.m. and 10:30 a.m.; and five
samples were collected between 1:30 p.m. and 4:15 p.m.
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Saliva Collection
To ensure optimal quality of the saliva, we asked participants not to eat,
drink (except plain water), smoke, or brush their teeth for one hour before
saliva collection. The participants rinsed their mouths with water, and we
provided an inert sugar-free gum to stimulate saliva flow. Saliva was collected
in polystyrene culture tubes that had been pretreated with sodium azide.
Following collection, the tubes were kept covered at room temperature for
18–24 hr to allow separation to occur. The tubes were then stored at −20◦C
until analysis.
Radioimmunoassays
Specimens were thawed at 4◦C and centrifuged at 3000 rpm for 15 min. Be-
cause we anticipated low concentrations of T in some of the women, we
submitted 2 mL of the supernatant to a double ether extraction and recon-
stituted it in one mL phosphate buffer. We then assayed the extract using a
single Coat-a-Count kit for total T (Diagnostic Products Corporation (DPC),
Los Angeles, CA), modified for use with saliva. The calibrators were diluted
1:20 and, to further increase detectability at the low end of the curve, we
added a 5 pg standard, giving a range of 5–800 pg. For the assay, 200 uL of
sample was pipetted into an antibody-coated tube, and 1 mL of 125I tracer
was added. The tubes were allowed to incubate for 22 hr at room temper-
ature, then decanted and counted in a gamma counter. All specimens were
assayed in duplicate. The sensitivity was calculated at 5 pg, and the intra-
assay coefficient of variation averaged across low, medium, and high pools
was 10%.
The DPC kit has demonstrated superior validity for the measurement
of T in women (Taieb et al., 2003). The antiserum is highly specific for T,
with negligible cross-reactivity with other steroids except dihydrotestosterone
(<3.5%). We did not include women taking oral contraceptives in the present
study, thus eliminating any risk of cross-reactions with progestogens in the
19-nortestosterone series.
The values used for statistical analysis are mean T concentrations across
the two duplicates.
RESULTS
Changes in bioavailable T and sexual desire were analyzed with 2 (time: pre-
versus posttreatment) × 2 (group: treatment versus reference) mixed effects
analyses of variance (ANOVA), using the Statistical Package for the Social
Sciences, v.11, for Windows. We used Tukey’s HSD post hoc tests to explore
statistically significant interactions.
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TABLE 1. Testosterone Levels and Sexual Desire Inventory (SDI) Scores as a Function of
Testosterone Treatment
Reference Treated
Pre vs. Treated vs.
Measure Pre Post Pre Post Post Cont Interaction
Testosterone range: 13.86a 12.50a 10.08a 29.49b ∗∗ ∗∗
5 pg/mL (min)–77.15 (max)
SDI total range: 12–89 63.08a 65.67a 28.13b 65.03a ∗∗∗ ∗∗ ∗∗∗
SDI dyadic scale; 36.35a 37.81a 16.08b 35.56a ∗∗∗ ∗∗ ∗∗∗
range: 7–54
SDI solitary autosexual 7.21a 7.96a 4.33b 10.06a ∗∗∗ ∗∗
scale; range: 2–23
Note. Means with common superscripts do not differ at the .05 level by Tukey’s Honestly Significant
Difference tests; ∗ = .05; ∗∗ = .01, ∗∗∗ = .001.
Testosterone (T) Levels
We removed two extreme outliers from the T analyses; one had T levels
over 150 standard deviations from the mean, the other was over 8.5 standard
deviations from the mean. This likely reflects blood contamination of the
saliva. One woman had a pretreatment T value below assay sensitivity and
was also excluded.
There was a significant Time × Group interaction effect, F (1, 28) =
14.64, p = .001, as well as a significant main effect of time, F (1, 28) = 11.06,
p = .002, and a trend for a main effect of group, F (1, 28) = 3.78, p = .062,
on levels of T. Post hoc tests (see Table 1) revealed no difference between
groups in pretreatment means, however, treated women exhibited signif-
icantly higher T posttreatment compared to pretreatment, q(4, 26) = 7.03,
p < .01, and significantly higher T posttreatment than did reference women,
q(4, 26) = 6.16, p < .01.
Sexual Desire
Some women skipped questions on the SDI, so the total SDI score (n = 5)
or the dyadic SDI score (n = 1) could not be calculated.
There was a significant interaction of Time × Group, F (1, 25) = 30.56,
p < .001, as well as significant main effects of time, F (1, 25) = 40.50, p <
.001, and group, F (1, 25) = 12.82, p = .001, on total SDI scores. Post hoc
tests revealed that treated women had significantly lower sexual desire pre-
compared with posttreatment, q(4, 25) = 9.44, p < .01. Treated women also
had significantly lower sexual desire prior to treatment, compared with refer-
ence women, q(4, 25) = 8.44, p < .01. We note that treated women’s overall
sexual desire following treatment was equivalent to reference women’s sex-
ual desire at that time.
180 S. M. van Anders et al.
Autosexual desire—the desire for self-stimulation—as measured by the
SDI solitary subscale, also showed a significant interaction of Time × Group,
F (1, 30) = 8.99, p = .005, as well as a main effect of time, F (1, 30) = 15.23,
p < .001. Post hoc tests revealed that prior to treatment, treated women had
significantly lower autosexual desire scores than they reported posttreatment,
q(4, 30) = 9.86, p < .01. We note that treated women’s autosexual desire,
following treatment, was equivalent to reference women’s sexual desire at
that time.
Desire for couple sexual interaction, as measured by the SDI dyadic
subscale, also showed a significant interaction of Time × Group, F (1, 29) =
27.97, p < .001, as well as main effects of time, F (1, 29) = 37.79, p < .001,
and group, F (1, 29) = 15.28, p = .001. Post hoc tests revealed that prior
to treatment, treatment group women had significantly lower dyadic sexual
desire than they did posttreatment, q(4, 29) = 8.99, p < .01. Prior to treat-
ment, treatment group women also had lower dyadic sexual desire than
did reference group women, q(4, 29) = 8.57, p < .01. We note that follow-
ing treatment, treatment group women’s levels of dyadic sexual desire were
equivalent to those of reference group women.
For nearly all indicators of sexual desire, reference group women did
not differ pre- to posttreatment; treatment group women reported less sexual
desire than did reference group women prior to treatment; and treatment
and reference group women reported equivalent sexual desire following
treatment.
Menopausal Status, Testosterone, and Sexual Desire
We analyzed menopausal status for exploratory reasons. Changes in bioavail-
able T and sexual desire were analyzed with a 2 (time: pre- versus posttreat-
ment) × 2 (group: treatment versus reference) × 2 (menopausal status: pre-
versus postmenopausal) repeated measures ANOVA. There were no signifi-
cant interactions involving menopausal status for either T or the SDI solitary
subscale. There was a significant interaction of Time × Menopausal Status,
F (1, 23) = 10.26, p < .004, as well as a significant interaction of Time ×
Group × Menopausal Status, F (1, 23) = 9.64, p = .005, for overall sexual
desire. Reference group women remained constant over time, whereas treat-
ment group women showed a significant increase in SDI scores to levels com-
parable to reference group women. Premenopausal treatment group women
appeared to have a larger increase in sexual desire than did Postmenopausal
Treatment Group women. There also was a significant interaction of Group
× Menopausal Status for the SDI dyadic subscale, F (1, 27) = 5.17, p = .031,
such that reference and treatment group women differed in dyadic sexual de-
sire, and premenopausal reference Group women had higher dyadic sexual
desire than did postmenopausal reference group women.
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DISCUSSION
The goal of this study was to investigate the effects of androgen treatment
without ERT on sexual desire in women presenting for treatment of HSD com-
pared with age-matched reference group women. This investigation showed
highly consistent positive effects of androgen treatment on bioavailable T and
on sexual desire levels among treated women. Because this pilot study was
not performed double-blind and did not include a placebo control group,
results should be interpreted with caution and viewed as preliminary clinical
findings. Following androgen administration, treated women exhibited signif-
icantly higher levels of T compared with pretreatment or reference women.
This is consistent with previous reports (e.g. Munnariz et al., 2002). In contrast
with Davis (1998), who stated that only women with hormonal components
to their sexual dysfunction would benefit from androgen replacement, our
study found an increase in sexual desire in treated women despite their hav-
ing baseline T levels equivalent to the reference group. Perhaps women with
HSD are more sensitive to T (see Bancroft, 2002, for a theoretical treatment
of these issues), a possibility that highlights the present gap in knowledge
regarding regular levels of androgens in women. This also suggests that HSD
diagnosis should not be dependent on androgen levels.
Treated women had significantly lower sexual desire scores on the SDI
than did reference group women at baseline, consistent with their subjective
complaints of low sexual desire. Consistent with previous reports (Guay,
2001; Munarriz et al., 2002), androgen administration led to increases in sex-
ual desire. Other studies of sexual parameters, including those of relevance to
sexual desire, also report increases following T administration (Goldstat et al.,
2003; Davis et al., 2003). Significantly higher scores on all scales of the SDI
were observed posttreatment for treated women compared to pretreatment.
Thus, androgen treatment seemed effective at increasing solitary desire, or
the desire for self-stimulation, as well as dyadic desire, or the desire for
partner-related stimulation. Further research should examine whether lower
doses of T, accompanied by fewer androgenic side effects, are as effective
at increasing sexual desire as those used in this study. Transdermal therapies
would also likely be less aversive to participants than injections.
Androgen treatment-related increases in sexual desire may have been
the result of expectancy effects in this study, although studies using T in
conjunction with ERT have found similar increases in sexual desire (e.g.,
Sherwin, 2002). Further clinical study should focus on randomized, double-
blind, placebo-controlled trials to definitively rule out expectancy effects. In
addition, T has beneficial effects on mood and energy, which may in turn
be associated with increases in sexual parameters (Bancroft, 2002; Davis
et al., 2003; Decker et al., 2003). It is possible that the increases in sexual
desire following T administration are secondary to positive effects on these
variables. Although women with HSD would still experience increased sexual
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desire with T administration, further study should determine whether T acts
to increase sexual desire directly or through mediating variables.
Although the etiology of HSD is complex and multifaceted, it appears
that hormonal treatment may be effective at increasing sexual desire, per-
haps even for women who do not show a baseline androgen deficiency.
Previous research has shown the beneficial effects of androgens in addition
to ERT in naturally postmenopausal women (Sherwin, 2002) and in surgi-
cally postmenopausal women (Gelfand, 1999). Correlational studies have
also found associations between increased androgens and increased sexual
desire (e.g., Riley & Riley, 2000). Munarriz et al. (2002) and Guay (2001)
both examined the effects of androgen supplementation on sexual desire,
but ours is the first study, to our knowledge, that statistically demonstrates
the effects of androgen supplementation on HSD in women using no other
exogenous hormones. As well, we used large enough samples in the present
study to explore potential interactions of menopausal status. Our findings
are in agreement with Tuiten et al. (2000), who found that testosterone ad-
ministration was associated with increased sexual lust in a small sample of
eight healthy premenopausal women but they extend these results to longer-
term treatment in a clinical population of women with HSD and to both pre-
and postmenopausal women, suggesting that T administration may be an
effective way of alleviating HSD.
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